Shield Therapeutics PLC Block Listing 6 Monthly Return (1728U)
March 31 2021 - 9:00AM
UK Regulatory
TIDMSTX
RNS Number : 1728U
Shield Therapeutics PLC
31 March 2021
Shield Therapeutics plc
("Shield" or the "Group")
Block Listing 6 Monthly Return
Date: 31 March 2021
Name of applicant: SHIELD THERAPEUTICS PLC
Name of scheme: S hield Therapeutics Retention Share Plan
----------------------------------------------
Period of return: From: 01 October 2020 To: 31 March 2021
------------------------ -------------------- ----- -----------------
Balance of unallotted securities under scheme(s) from previous
return: 54,219
----------------------------------------------
Plus: The amount by which the block scheme(s) has been increased NIL
since the date of the last
return (if any increase has been applied for):
----------------------------------------------
Less: Number of securities issued/allotted under scheme(s) during
period (see LR3.5.7G): -14,425
----------------------------------------------
Equals: Balance under scheme(s) not yet issued/allotted at end of
period: 39,794
----------------------------------------------
Name of applicant: SHIELD THERAPEUTICS PLC
Name of scheme: Shield Therapeutics plc 2016 Company Share Option Plan
-----------------------------------------------------------
Period of return: From: 01 October 2020 To: 31 March 2021
------------------------ -------------------------- ------- ----------------------
Balance of unallotted securities under scheme(s) from
previous return: 388,079
-----------------------------------------------------------
Plus: The amount by which the block scheme(s) has been NIL
increased since the date of the last
return (if any increase has been applied for):
-----------------------------------------------------------
Less: Number of securities issued/allotted under NIL
scheme(s) during period (see LR3.5.7G):
-----------------------------------------------------------
Equals: Balance under scheme(s) not yet issued/allotted
at end of period: 388,079
-----------------------------------------------------------
Name of applicant: SHIELD THERAPEUTICS PLC
Name of scheme: The Shield Therapeutics plc 2016 Long Term Incentive Plan
--------------------------------------------------------------
Period of return: From: 01 October 2020 To: 31 March 2021
------------------------ ---------------------------- ------- -----------------------
Balance of unallotted securities under scheme(s) from
previous return: 171,883
--------------------------------------------------------------
Plus: The amount by which the block scheme(s) has NIL
been increased since the date of the last
return (if any increase has been applied for):
--------------------------------------------------------------
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G): -147,610
--------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period: 24,273
--------------------------------------------------------------
Name of applicant: SHIELD THERAPEUTICS PLC
Name of scheme: Shield Therapeutics Retention and Performance Share Plan
-------------------------------------------------------------
Period of return: From: 01 October 2020 To: 31 March 2021
------------------------ --------------------------- ------- -----------------------
Balance of unallotted securities under scheme(s) from
previous return: 1,885,819
-------------------------------------------------------------
Plus: The amount by which the block scheme(s) has been
increased since the date of the last
return (if any increase has been applied for): 2,500,000*
-------------------------------------------------------------
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G): -1,207,543
-------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period: 3,178,276
-------------------------------------------------------------
*Please note this number is further to the block listing applied
for on the 24(th) March 2021 and admitted on 30(th) March 2021.
This block listing has been allocated to the Shield Therapeutics
Retention and Performance Share Plan in entirety.
Name of contact: Lucy Huntington-Bailey
Telephone number of contact: +44 (0) 191 511 8500
-----------------------
For further information, please contact:
Shield Therapeutics plc +44 (0) 191 511 8500
Tim Watts (CEO)
Lucy Huntington-Bailey, (Company Secretary
and General Counsel)
Peel Hunt LLP - Nominated Adviser & Joint
Broker +44 (0) 20 7148 8900
James Steel / Christopher Golden
finnCap Ltd - Joint Broker +44 (0) 20 7220 0500
Geoff Nash / Alice Lane / Matthew
Radley
Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Lianne Cawthorne or shield@walbrookpr.com
About Shield
Shield is a commercial stage, pharmaceutical company with a
focus on addressing iron deficiency with its lead product Feraccru
(R) /Accrufer (R) (ferric maltol), a novel, stable, non-salt based
oral therapy for adults with iron deficiency with or without
anaemia.
Shield's lead product, Feraccru(R)/Accrufer(R), has been
approved for use in the United States, European Union, UK and
Switzerland and has exclusive IP rights until the mid-2030s. The
Group plans to launch Accrufer(R) in the US during 2021 through a
highly experienced sales and marketing team. Feraccru(R) is already
being commercialised in the UK and European Union by Norgine B.V.,
who also have the marketing rights in Australia and New Zealand.
Shield also has an exclusive licence agreement with Beijing
Aosaikang Pharmaceutical Co., Ltd., for the development and
commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong,
Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLREADDFDSEFEFA
(END) Dow Jones Newswires
March 31, 2021 10:00 ET (14:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2023 to Apr 2024
